Anup Kumar Halder

Dr. Anup Kumar Halder

CeNT, University of Warsaw, Warsaw, Mazowieckie, Poland
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Journal of Systems Architecture
Verified
Journal Article
Closed access
SBSayantani Basu
Sayantani Basu
Marimuthu KaruppiahMarimuthu Karuppiah
Marimuthu Karuppiah
MNMita Nasipuri
Mita Nasipuri
Anup Kumar HalderAnup Kumar Halder
Anup Kumar Halder
NRNiranchana Radhakrishnan
Niranchana Radhakrishnan

27 August 2021 in Methods
Verified
Journal Article
Closed access
Sovan SahaSovan Saha
Sovan Saha
Anup Kumar HalderAnup Kumar Halder
Anup Kumar Halder
SBSoumyendu Sekhar Bandyopadhyay
Soumyendu Sekhar Bandyopadhyay
PCPiyali Chatterjee
Piyali Chatterjee
MNMita Nasipuri
Mita Nasipuri
SBSubhadip Basu
Subhadip Basu

26 September 2017 in Briefings in Functional Genomics
Verified
Journal Article
Open access
PDF file
Anup Kumar HalderAnup Kumar Halder
Anup Kumar Halder
PDPritha Dutta
Pritha Dutta
MKMahantapas Kundu
Mahantapas Kundu
SBSubhadip Basu
Subhadip Basu
MNMita Nasipuri
Mita Nasipuri
Identification of potential virus–host interactions is useful and vital to control the highly infectious virus-caused diseases. This may contribute toward development of new drugs to treat the viral infections. Recently, database records of clinically and experimentally validated interactions between a small set of human proteins and Ebola virus (EBOV) have been published. Using the information of the known human interaction partners of EBOV, our main objective is to identify a set of proteins that may interact with EBOV proteins. Here, we first review the state-of-the-art, computational methods used for prediction of novel virus–host interactions for infectious diseases followed by a case study on EBOV–human interactions. The assessment result shows that the predicted human host proteins are highly similar with known human interaction partners of EBOV in the context of structure and semantics and are responsible for similar biochemical activities, pathways and host–pathogen relationships.

Verified
Journal Article
Open access
PDF file
MZMonika Zaręba-Kozioł
Monika Zaręba-Kozioł
ABAnna Bartkowiak-Kaczmarek
Anna Bartkowiak-Kaczmarek
MRMatylda Roszkowska
Matylda Roszkowska
KBKrystian Bijata
Krystian Bijata
IFIzabela Figiel
Izabela Figiel
JWJakub Wlodarczyk
Jakub Wlodarczyk
Although sex differences in the brain are prevalent, the knowledge about mechanisms underlying sex-related effects on normal and pathological brain functioning is rather poor. It is known that female and male brains differ in size and connectivity. Moreover, those differences are related to neuronal morphology, synaptic plasticity, and molecular signaling pathways. Among different processes assuring proper synapse functions are posttranslational modifications, and among them, S-palmitoylation (S-PALM) emerges as a crucial mechanism regulating synaptic integrity. Protein S-PALM is governed by a family of palmitoyl acyltransferases, also known as DHHC proteins. Here we focused on the sex-related functional importance of DHHC7 acyltransferase because of its S-PALM action over different synaptic proteins as well as sex steroid receptors. Using the mass spectrometry-based PANIMoni method, we identified sex-dependent differences in the S-PALM of synaptic proteins potentially involved in the regulation of membrane excitability and synaptic transmission as well as in the signaling of proteins involved in the structural plasticity of dendritic spines. To determine a mechanistic source for obtained sex-dependent changes in protein S-PALM, we analyzed synaptoneurosomes isolated from DHHC7-/- (DHHC7KO) female and male mice. Our data showed sex-dependent action of DHHC7 acyltransferase. Furthermore, we revealed that different S-PALM proteins control the same biological processes in male and female synapses.

1 October 2020 in Methods
Verified
Journal Article
Closed access
Anup Kumar HalderAnup Kumar Halder
Anup Kumar Halder
MDMichał Denkiewicz
Michał Denkiewicz
KSKaustav Sengupta
Kaustav Sengupta
SBSubhadip Basu
Subhadip Basu
DPDariusz Plewczynski
Dariusz Plewczynski

30 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
Sovan SahaSovan Saha
Sovan Saha
PCPiyali Chatterjee
Piyali Chatterjee
Anup Kumar HalderAnup Kumar Halder
Anup Kumar Halder
MNMita Nasipuri
Mita Nasipuri
SBSubhadip Basu
Subhadip Basu
DPDariusz Plewczynski
Dariusz Plewczynski
Recent research has highlighted that a large section of druggable protein targets in the Human interactome remains unexplored for various diseases. It might lead to the drug repurposing study and help in the in-silico prediction of new drug-human protein target interactions. The same applies to the current pandemic of COVID-19 disease in global health issues. It is highly desirable to identify potential human drug targets for COVID-19 using a machine learning approach since it saves time and labor compared to traditional experimental methods. Structure-based drug discovery where druggability is determined by molecular docking is only appropriate for the protein whose three-dimensional structures are available. With machine learning algorithms, differentiating relevant features for predicting targets and non-targets can be used for the proteins whose 3-D structures are unavailable. In this research, a Machine Learning-based Drug Target Discovery (ML-DTD) approach is proposed where a machine learning model is initially built up and tested on the curated dataset consisting of COVID-19 human drug targets and non-targets formed by using the Therapeutic Target Database (TTD) and human interactome using several classifiers like XGBBoost Classifier, AdaBoost Classifier, Logistic Regression, Support Vector Classification, Decision Tree Classifier, Random Forest Classifier, Naive Bayes Classifier, and K-Nearest Neighbour Classifier (KNN). In this method, protein features include Gene Set Enrichment Analysis (GSEA) ranking, properties derived from the protein sequence, and encoded protein network centrality-based measures. Among all these, XGBBoost, KNN, and Random Forest models are satisfactory and consistent. This model is further used to predict novel COVID-19 human drug targets, which are further validated by target pathway analysis, the emergence of allied repurposed drugs, and their subsequent docking study.